HRP20150026T1 - 8-klor-3-pentil-3,7-dihidro-1h-purin-2,6-dion 2-amino-2-(hidroksimetil)-1,3-propandiol anhidrat za lijeäśenje bolesti - Google Patents
8-klor-3-pentil-3,7-dihidro-1h-purin-2,6-dion 2-amino-2-(hidroksimetil)-1,3-propandiol anhidrat za lijeäśenje bolesti Download PDFInfo
- Publication number
- HRP20150026T1 HRP20150026T1 HRP20150026AT HRP20150026T HRP20150026T1 HR P20150026 T1 HRP20150026 T1 HR P20150026T1 HR P20150026A T HRP20150026A T HR P20150026AT HR P20150026 T HRP20150026 T HR P20150026T HR P20150026 T1 HRP20150026 T1 HR P20150026T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- compound according
- crystalline form
- treatment
- hydroxymethyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (14)
1. Spoj, naznačen time što je kristalni 8-klor-3-pentil-3,7-dihidro-1H-purin-2,6-dion tris(hidroksimetil)aminometan anhidrat (Formula (IA):
[image]
2. Spoj prema zahtjevu 1, gdje kristalni oblik spoja je naznačen time što XRPD uzorak sadržava sljedeće pikove:
[image]
3. Spoj prema bilo kojem od zahtjeva 1 do 2, gdje kristalni oblik spoja je naznačen time što ima XRPD uzorak koji izgleda kao što je prikazano na Slici 2.
4. Spoj prema bilo kojem od zahtjeva 1 do 3 gdje kristalni oblik spoja je naznačen time što ima endotermno taljenje s temperaturom početka taljenja od 212 ± 2 °C u DSC termogramu.
5. Spoj prema bilo kojem od zahtjeva 1 do 4 gdje kristalni oblik spoja je naznačen time što ima sljedeće apsorpcijske pikove u ATR-IR spektru krutog produkta: 3370, 3041, 2946, 2858, 1680, 1656, 1528, 1266, 1243, 1078, 1068, 1049 ± 1 cm-1.
6. Spoj prema bilo kojem od zahtjeva 1 do 5 gdje kristalni oblik spoja je naznačen time što ima ATR infracrveni spektar koji izgleda kao što je prikazano na Slici 6.
7. Kombinacija, naznačena time što sadržava a) spoj kao što je definirano u bilo kojem od prethodnih zahtjeva 1 do 6 i b) jedno ili više terapijski aktivnih sredstava.
8. Spoj kao što je definirano u bilo kojem od zahtjeva 1 do 6, naznačen time što se koristi u terapiji.
9. Spoj prema zahtjevu 8, naznačen time što se upotrebljava za liječenje miješane dislipidemije, dijabetičke dislipidemije ili hiperlipoproteinemije.
10. Spoj prema zahtjevu 8, naznačen time što se upotrebljava za liječenje diabetes mellitus-a tipa II.
11. Spoj prema zahtjevu 8, naznačen time što se upotrebljava za liječenje dijabetičke dislipidemije, miješane dislipidemije, otkazivanja srca, hiperkolesterolemije, kardiovaskularne bolesti, ateroskleroze, arterioskleroze, hipertrigliceridemije, diabetes mellitus-a tipa II, dijabetesa tipa II, otpornosti na inzulin, hiperlipidemije, anoreksije nervose, pretilosti, bolesti koronarnih arterija, tromboze, angine, kroničnog otkazivanja bubrega, periferne vaskularne bolesti ili kapi.
12. Spoj prema zahtjevu 8, naznačen time što se upotrebljava za liječenje multiple skleroze.
13. Farmaceutski pripravak, naznačen time što sadržava: a) spoj kao što je definirano u bilo kojem od zahtjeva 1 do 6 i b) jedan ili više farmaceutski prihvatljivih nosača.
14. Postupak za dobivanje spoja kao što je definirano u bilo kojem od zahtjeva 1 do 6, naznačen time što spomenuti postupak sadržava korak miješanja spoja Formule (A)
[image]
s tris(hidroksimetil)aminometanom.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12059608P | 2008-12-08 | 2008-12-08 | |
| PCT/US2009/066941 WO2010068581A1 (en) | 2008-12-08 | 2009-12-07 | Novel compounds |
| EP09832421.3A EP2370440B1 (en) | 2008-12-08 | 2009-12-07 | 8-Chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione 2-amino-2-(hydroxymethyl)-1,3-propanediol anhydrate for the treatment of diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150026T1 true HRP20150026T1 (hr) | 2015-02-13 |
Family
ID=42243044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150026AT HRP20150026T1 (hr) | 2008-12-08 | 2009-12-07 | 8-klor-3-pentil-3,7-dihidro-1h-purin-2,6-dion 2-amino-2-(hidroksimetil)-1,3-propandiol anhidrat za lijeäśenje bolesti |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US9163024B2 (hr) |
| EP (1) | EP2370440B1 (hr) |
| JP (1) | JP5666464B2 (hr) |
| KR (1) | KR101743783B1 (hr) |
| CN (1) | CN102245606B (hr) |
| AU (1) | AU2009324811B2 (hr) |
| BR (1) | BRPI0922134A2 (hr) |
| CA (1) | CA2746316C (hr) |
| CY (1) | CY1116032T1 (hr) |
| DK (1) | DK2370440T3 (hr) |
| EA (1) | EA020037B1 (hr) |
| ES (1) | ES2527354T3 (hr) |
| HR (1) | HRP20150026T1 (hr) |
| IL (1) | IL213032A (hr) |
| MX (1) | MX2011006022A (hr) |
| PL (1) | PL2370440T3 (hr) |
| PT (1) | PT2370440E (hr) |
| RS (1) | RS53777B1 (hr) |
| SI (1) | SI2370440T1 (hr) |
| SM (1) | SMT201500012B (hr) |
| WO (1) | WO2010068581A1 (hr) |
| ZA (1) | ZA201103397B (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1781657E (pt) | 2004-02-14 | 2013-05-23 | Glaxosmithkline Ip Dev Ltd | Medicamentos com actividade no receptor hm74a |
| JP2009504592A (ja) | 2005-08-10 | 2009-02-05 | スミスクライン・ビーチャム・コーポレイション | 選択的ｈｍ７４ａアゴニストとしてのキサンチン誘導体 |
| CA2868033A1 (en) * | 2012-03-22 | 2013-09-26 | Transtech Pharma, Llc | Tris(hydroxymethyl)aminomethane salts of a small-molecule glp1r agonist and pharmaceutical compositions and uses thereof |
| AU2024229006A1 (en) * | 2023-02-27 | 2025-09-18 | Shanton Pharma Pte. Ltd. | Crystal form of 8-chloro-3-pentyl-3,7-dihydro-1h-purin-2,6-dione compound and preparation method therefor |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3657327A (en) * | 1970-06-01 | 1972-04-18 | Upjohn Co | Prostaglandin salts of tris(hydroxymethyl)aminomethane |
| US4647585A (en) * | 1984-11-08 | 1987-03-03 | E. R. Squibb & Sons, Inc. | Bicycloheptane substituted ethers |
| WO2001043692A2 (en) * | 1999-12-15 | 2001-06-21 | Smithkline Beecham Corporation | SALTS OF Cis-4-CYANO-4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]CYCLOHEXANE-1-CARBOXYLIC ACID |
| US20030013905A1 (en) | 2002-06-10 | 2003-01-16 | Huang Guishu Kris | Salts of cis-4-cyano-4[3(cyclopentyloxy)-4-methoxyphenyl]cyclohexane-1-carboxylic acid |
| PT1781657E (pt) | 2004-02-14 | 2013-05-23 | Glaxosmithkline Ip Dev Ltd | Medicamentos com actividade no receptor hm74a |
| US20090209561A1 (en) | 2004-10-22 | 2009-08-20 | Richard Jonathan Daniel Hatley | Xanthine Derivatives with HM74A Receptor Activity |
| GB0423568D0 (en) * | 2004-10-22 | 2004-11-24 | Smithkline Beecham Corp | Novel compounds |
| GB0516464D0 (en) * | 2005-08-10 | 2005-09-14 | Smithkline Beecham Corp | Novel compounds |
| JP2009504592A (ja) | 2005-08-10 | 2009-02-05 | スミスクライン・ビーチャム・コーポレイション | 選択的ｈｍ７４ａアゴニストとしてのキサンチン誘導体 |
-
2009
- 2009-12-07 HR HRP20150026AT patent/HRP20150026T1/hr unknown
- 2009-12-07 JP JP2011539772A patent/JP5666464B2/ja not_active Expired - Fee Related
- 2009-12-07 CN CN200980148973.7A patent/CN102245606B/zh not_active Expired - Fee Related
- 2009-12-07 US US13/133,486 patent/US9163024B2/en not_active Expired - Fee Related
- 2009-12-07 KR KR1020117012975A patent/KR101743783B1/ko not_active Expired - Fee Related
- 2009-12-07 RS RS20150086A patent/RS53777B1/en unknown
- 2009-12-07 BR BRPI0922134-4A patent/BRPI0922134A2/pt not_active Application Discontinuation
- 2009-12-07 SI SI200931113T patent/SI2370440T1/sl unknown
- 2009-12-07 CA CA2746316A patent/CA2746316C/en not_active Expired - Fee Related
- 2009-12-07 MX MX2011006022A patent/MX2011006022A/es active IP Right Grant
- 2009-12-07 WO PCT/US2009/066941 patent/WO2010068581A1/en active Application Filing
- 2009-12-07 PL PL09832421T patent/PL2370440T3/pl unknown
- 2009-12-07 AU AU2009324811A patent/AU2009324811B2/en not_active Ceased
- 2009-12-07 ES ES09832421.3T patent/ES2527354T3/es active Active
- 2009-12-07 PT PT98324213T patent/PT2370440E/pt unknown
- 2009-12-07 DK DK09832421.3T patent/DK2370440T3/en active
- 2009-12-07 EA EA201170783A patent/EA020037B1/ru not_active IP Right Cessation
- 2009-12-07 EP EP09832421.3A patent/EP2370440B1/en active Active
-
2011
- 2011-05-10 ZA ZA2011/03397A patent/ZA201103397B/en unknown
- 2011-05-19 IL IL213032A patent/IL213032A/en not_active IP Right Cessation
-
2014
- 2014-12-16 CY CY20141101047T patent/CY1116032T1/el unknown
-
2015
- 2015-01-16 SM SM201500012T patent/SMT201500012B/xx unknown
- 2015-08-31 US US14/840,549 patent/US20150366870A1/en not_active Abandoned
-
2016
- 2016-10-11 US US15/289,996 patent/US20170027945A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2746316A1 (en) | 2010-06-17 |
| JP2012511028A (ja) | 2012-05-17 |
| KR20110097816A (ko) | 2011-08-31 |
| IL213032A0 (en) | 2011-07-31 |
| CA2746316C (en) | 2017-01-03 |
| US9163024B2 (en) | 2015-10-20 |
| EA201170783A1 (ru) | 2011-12-30 |
| US20110251218A1 (en) | 2011-10-13 |
| RS53777B1 (en) | 2015-06-30 |
| BRPI0922134A2 (pt) | 2015-08-18 |
| CN102245606A (zh) | 2011-11-16 |
| DK2370440T3 (en) | 2014-12-08 |
| SMT201500012B (it) | 2015-05-03 |
| AU2009324811B2 (en) | 2013-01-24 |
| PT2370440E (pt) | 2015-01-14 |
| EP2370440A4 (en) | 2012-05-30 |
| ZA201103397B (en) | 2012-01-25 |
| EP2370440B1 (en) | 2014-11-12 |
| CY1116032T1 (el) | 2017-01-25 |
| IL213032A (en) | 2015-02-26 |
| PL2370440T3 (pl) | 2015-05-29 |
| EA020037B1 (ru) | 2014-08-29 |
| WO2010068581A1 (en) | 2010-06-17 |
| JP5666464B2 (ja) | 2015-02-12 |
| EP2370440A1 (en) | 2011-10-05 |
| ES2527354T3 (es) | 2015-01-22 |
| US20170027945A1 (en) | 2017-02-02 |
| MX2011006022A (es) | 2011-06-28 |
| KR101743783B1 (ko) | 2017-06-05 |
| AU2009324811A1 (en) | 2011-06-23 |
| SI2370440T1 (sl) | 2015-02-27 |
| CN102245606B (zh) | 2014-08-20 |
| US20150366870A1 (en) | 2015-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI4157832T3 (fi) | Glp-1r-agonistien suola- ja kidemuotoja ja niiden käyttötarkoituksia | |
| HRP20150026T1 (hr) | 8-klor-3-pentil-3,7-dihidro-1h-purin-2,6-dion 2-amino-2-(hidroksimetil)-1,3-propandiol anhidrat za lijeäśenje bolesti | |
| CZ30899A3 (cs) | Substituovaný pyridin a bifenyl jako antihypercholesterinemické, antihyperlipoproteinemické a antihyperglykemické přípravky | |
| CN115244056A (zh) | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 | |
| JP2021521265A (ja) | Ｇｌｐ−１受容体アゴニストおよびその使用 | |
| KR20190094433A (ko) | Glp-1 수용체 작용제 및 이의 용도 | |
| EP2041072B1 (en) | Cxcr2 antagonists | |
| JP2011515341A5 (hr) | ||
| BRPI0706780A2 (pt) | compostos e composições como moduladores de ppar | |
| JP2017521457A5 (hr) | ||
| NO343371B1 (no) | Nye forbindelser med DGAT1-aktivitet, farmasøytiske sammensetninger inneholdende slike og anvendelse derav | |
| EP1636205A1 (en) | Pyridinyl carbamates as hormone-sensitive lipase inhibitors | |
| NO20056056L (no) | N-actyl nitrogenheterocykler som ligander av peroksisom-proliferatoraktiverte reseptorer | |
| WO2009056070A1 (fr) | Dérivé éther de l'acide aromatique ligustrazine, son procédé de préparation, composition pharmaceutique et application | |
| AU2006311524A1 (en) | Compounds and compositions as PPAR modulators | |
| WO2014025942A1 (en) | Nmda receptor modulators and uses related thereto | |
| JP2008500354A (ja) | Ｐｐａｒモジュレーターとしての化合物および組成物 | |
| TWI821237B (zh) | 用於製備可溶性鳥苷酸環化酶刺激劑之新穎方法及中間物 | |
| WO2011151436A2 (en) | Novel compounds, method for use them and pharmaceutical composition containing them | |
| JP2012511028A5 (hr) | ||
| AU2003287972A1 (en) | Bifunctional phenyliso(thio)cyanates; method and intermediate products for the production thereof | |
| JP2007537289A (ja) | Ｐｐａｒモジュレーターとしての化合物および組成物 | |
| CA2626443A1 (en) | Oxazole and thiazole ppar modulators | |
| JP7729891B2 (ja) | 甲状腺ホルモン受容体β選択のアゴニスト化合物、その医薬組成物および用途 | |
| JP7551217B2 (ja) | ジアシルグリセロールアシルトランスフェラーゼ２阻害剤として有用な新規ビアリール誘導体及びその使用 |